• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

    10/2/23 7:00:00 AM ET
    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DNLI alert in real time by email

    CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023.

    (PRNewsfoto/Flagship Pioneering)

    Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse therapeutic areas. Most recently he was Senior Vice President, Head of Research, leading a large group of scientists and physicians focused on combining the science of immunology, human genetics and genomics with advanced technologies to identify novel drug targets, discover new therapeutic modalities, and demonstrate proof of mechanism in clinical studies. The work from his group has led to multiple IND filings and transition of multiple novel medicines into clinical development. Before joining GSK, John was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, and he was an attending physician on the academic cardiology service.

    "John's two decades of success driving novel programs from discovery to validation to the clinic will be an excellent addition to both ProFound and to Flagship's ecosystem," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Strategic Oversight Board Chairman of ProFound Therapeutics. "John's expertise navigating the discovery and development of new medicines will be essential as ProFound pioneers the expanded proteome to create therapeutics that would not have been previously possible."

    "We've made significant advances with our ProFoundry™ Platform, which is a wellspring of first-in-class therapeutic opportunities," said Avak Kahvejian, Ph.D., Flagship Pioneering General Partner and Founding CEO of ProFound Therapeutics. "At this crucial stage in the company's growth, we're thrilled to welcome John to the team and look forward to leveraging his leadership experience and successful R&D track record as we reveal a universe of novel therapeutic targets and develop an initial pipeline of new medicines."

    "I'm honored to join the outstanding team at Flagship Pioneering and to have the opportunity to lead the talented team at ProFound who are redefining what we know about human biology with the ProFoundry Platform," said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner. "The identification of a whole new world of previously unknown proteins has enabled the exciting opportunity for ProFound to develop many new classes of drug targets across diverse therapeutic indications."  

    About John Lepore, M.D.

    John Lepore, M.D. was most recently Senior Vice President, Head of Research at GSK where he led a large organization of scientists and physicians focused on leveraging the science of immunology, human genetics and genomics, and advanced technologies to identify novel drug targets, discover new therapeutic molecules, and demonstrate proof of mechanism in clinical studies. 

    Dr. Lepore joined GSK in 2006 and has held roles of increasing responsibility including VP of Clinical Pharmacology and Discovery Medicine, VP and Head of the Heart Failure Discovery Performance Unit, SVP and Head of the Metabolic Pathways and Cardiovascular Therapeutic Area Unit, and SVP R&D Pipeline responsible for end-to-end R&D activities across multiple therapeutic areas. He was also Interim Head of Business Development and played a key role in multiple preclinical and clinical deals to augment the GSK pipeline.

    Before joining GSK, Dr. Lepore was on the faculty of the Cardiovascular Medicine Division of the Department of Medicine at the University of Pennsylvania, where his lab investigated the transcriptional regulation of cardiovascular development and he was attending physician on the academic cardiology service. 

    Dr. Lepore received his B.S. in Biology from the University of Scranton and his medical degree from Harvard Medical School where he was a Howard Hughes Medical Institute Research Scholar. He subsequently trained in internal medicine and cardiology and served as Medical Chief Resident at Massachusetts General Hospital, with post-doctoral training at the Harvard School of Public Health.

    Dr. Lepore has been on the Board of Directors of ViiV Healthcare, the Altius Institute, and the Biotechnology Innovation Organization (BIO), the Scientific Advisory Boards of Medicxi Ventures and Hatteras Ventures, and the Innovation Growth Board of Mass General Brigham. At GSK, he chaired the Research Review Board and Research Investment Board responsible for capital allocation and project prioritization.

    About ProFound™ Therapeutics

    ProFound Therapeutics is pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines. The company's ProFoundry Platform uses state-of-the-art protein detection technologies to systematically identify and validate proteins and dissect their therapeutic potential. The result is an ever-expanding database of tens of thousands of novel proteins, including their connectivity, functionality, and roles in health and disease. ProFound Therapeutics was founded by Flagship Pioneering in 2020. For more information, please visit www.profoundtx.com.

    About Flagship Pioneering

    Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $90 billion in aggregate value. To date, Flagship has deployed over $3.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $26 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 44 companies, including Denali Therapeutics (NASDAQ:DNLI), Foghorn Therapeutics (NASDAQ:FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ:MRNA), Omega Therapeutics (NASDAQ:OMGA), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB) and Tessera Therapeutics. For more information on Flagship, please visit www.flagshippioneering.com.

    Media Contact:

    [email protected] 

    ProFound Therapeutics

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-appoints-john-lepore-as-ceo-partner-and-ceo-of-profound-therapeutics-301943851.html

    SOURCE Flagship Pioneering

    Get the next $DNLI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNLI
    $FHTX
    $MCRB
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Seres Therapeutics Inc.
    $MCRB
    5/8/2025$6.00Buy → Neutral
    Chardan Capital Markets
    Foghorn Therapeutics Inc.
    $FHTX
    4/23/2025$9.00Mkt Outperform
    Citizens JMP
    Denali Therapeutics Inc.
    $DNLI
    4/10/2025Neutral → Overweight
    Cantor Fitzgerald
    Sana Biotechnology Inc.
    $SANA
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Sana Biotechnology Inc.
    $SANA
    3/14/2025$7.00Buy
    Jefferies
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    Denali Therapeutics Inc.
    $DNLI
    3/7/2025$41.00 → $33.00Overweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    2/18/2025$111.00 → $45.00Overweight → Equal Weight
    Barclays
    More analyst ratings

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Financials

    Live finance-specific insights

    See more
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

      CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on May 7, 2025 at 8:30 a.m. ET to discuss first quarter 2025 financial results and provide business updates. To access the conference call, please dial 800-715-9871 (domestic) or 646-307-1963 (international) and reference the conference ID number 4618787. To join the live webcast, please visit the "Investors and News" section of the Seres website at www.serestherapeutics.com. A webcast replay will be available on the Seres website beginning approximately two hours aft

      4/23/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

      Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study provides support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) at day 30 post-HSCT; Company expects to submit draft study protocol to FDA in Q2 2025 SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, are consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support potential for live biotherapeutics to address inflammatory and immune diseases Company advances SER-155 strategic partnership discussions to acce

      3/13/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Foghorn Therapeutics Appoints Neil Gallagher and Stuart Duty to its Board of Directors

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced the election of Neil Gallagher, M.D., Ph.D., and Stuart Duty, to its Board of Directors. "Neil and Stuart are experienced leaders with decades of deep and multifaceted understanding of the biotechnology industry," said Adrian Gottschalk, President and Chief Executive Officer of Foghorn. "We are pleased to welcome them to our Board of Directors and will leverage their strategic insights as we further advance our pipeline." Dr. Gallagher

      5/1/25 7:00:00 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:27:16 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

      4 - Moderna, Inc. (0001682852) (Issuer)

      3/4/25 4:24:36 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Gallagher Neil

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:04:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Duty Stuart

      4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:03:21 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Gallagher Neil

      3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)

      5/2/25 4:01:44 PM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seres Therapeutics downgraded by Chardan Capital Markets with a new price target

      Chardan Capital Markets downgraded Seres Therapeutics from Buy to Neutral and set a new price target of $6.00

      5/8/25 8:27:44 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citizens JMP initiated coverage on Foghorn Therapeutics with a new price target

      Citizens JMP initiated coverage of Foghorn Therapeutics with a rating of Mkt Outperform and set a new price target of $9.00

      4/23/25 8:16:18 AM ET
      $FHTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Denali Therapeutics from Neutral to Overweight

      4/10/25 8:28:39 AM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    SEC Filings

    See more
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Sana Biotechnology Inc.

      S-8 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:32:51 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Sana Biotechnology Inc.

      10-Q - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:10:02 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sana Biotechnology Reports First Quarter 2025 Financial Results and Business Updates

      Presented positive 4- and 12-week clinical results of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome immune recognition, while continuing to function and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B-cell depletion using a surrogate for SG299, an in vivo CAR T with CD8-targeted fusogen delivery of a CD19-direc

      5/8/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

      In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for the prevention of bloodstream infections (BSIs) in adults undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) for the treatment of hematological malignancies SER-155 Phase 1b placebo-controlled study exploratory translational biomarker data reinforce intended mechanisms of action, consistent with clinical results that showed a significant reduction (77% relative risk reduction) in BSIs, and support broader potential for Seres' live biotherapeutics to address inflammatory and immune diseases Seres advancing SER-155 strategic partnership discussions i

      5/7/25 7:00:00 AM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

      SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business highlights. "The completion of our BLA submission for tividenofusp alfa represents a pivotal milestone—not only in our commitment to delivering a potentially transformative therapy to individuals living with Hunter syndrome, but also in Denali's evolution as a fully integrated, late-stage development and commercial organization," said Ryan Watts, Ph.D., CEO of Denali Therapeutics. "We are now preparing for commercial launch in late 2025 or early 2026. If approved, tividenofusp alfa would be t

      5/6/25 4:01:00 PM ET
      $DNLI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 26, 2023 - FDA Approves First Orally Administered Fecal Microbiota Product for the Prevention of Recurrence of Clostridioides difficile Infection

      For Immediate Release: April 26, 2023 Today, the U.S. Food and Drug Administration approved Vowst, the first fecal microbiota product that is taken orally. Vowst is approved for the prevention of recurrence of Clostridioides difficile (C. difficile) infection (CDI) in individuals 18 years of age and older, following antibacterial treatment for recurrent CDI.  “Today’s approval provides patients and healthcare p

      4/26/23 6:04:21 PM ET
      $MCRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

      For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

      11/30/20 5:12:14 PM ET
      $MRNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DNLI
    $FHTX
    $MCRB
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care